BioWorld - Friday, December 5, 2025

Articles Tagged with ''Regeneron Pharmaceuticals Inc.''

Dollar sign, up arrow

Strong clinical data bumps biopharma stocks to a high point

Nov. 17, 2022
By Karen Carey
An uptick in positive clinical data reported in recent months has helped nudge the BioWorld Biopharmaceutical Index (BBI) to its highest point this year. BBI is up by 15.58%, significantly higher than the 1.36% increase recorded at the end of August, just as statistically significant clinical results began to roll in from a number of biopharma companies.
Read More
Joint pain illustration

Chapter closes on NGF pain drugs as Regeneron axes fasinumab

Nov. 4, 2022
By Richard Staines
Once pharma’s great hope to replace opioid painkillers, it looks like the end for nerve growth factor (NGF) inhibitors after Regeneron Pharmaceuticals Inc. quietly axed fasinumab, the late-stage painkilling injection it was developing in partnership with Teva Pharmaceuticals Ltd. and Mitsubishi Tanabe Pharma Corp.
Read More

WHO pulls COVID-19 recommendations from GSK-Vir, Regeneron MAbs

Sep. 16, 2022
By Lee Landenberger
What was once effective is now a non-starter. Newly updated guidelines from the World Health Organization (WHO) caution against using the COVID-19 treatments sotrovimab, from GSK plc and Vir Biotechnology Inc., and Regen-Cov (casirivimab + imdevimab), from Regeneron Pharmaceuticals Inc. Omicron, the group said, has rendered the monoclonal antibodies ineffective.
Read More

Regeneron sees market strength in new Eylea data

Sep. 9, 2022
By Lee Landenberger

Success in two pivotal studies of high dose Eylea (aflibercept) has significantly strengthened Regeneron Pharmaceuticals Inc.’s market position. But the company will face stiff competition from biosimilars and Roche Holding Group’s recently approved Vabysmo. After struggling for much of the year, the Tarrytown, N.Y.-based company’s stock (NASDAQ: REGN) rose about 20% this week. It closed 2% upward on Sept. 9 at $724.32 per share.


Read More
Ebola virus

Ebola losing ‘killer’ status to MAbs

Aug. 22, 2022
By Mari Serebrov
Regeneron Pharmaceuticals Inc.’s Inmazeb and Ridgeback Biotherapeutics LP’s Ebanga earned a ringing endorsement from the World Health Organization (WHO) in its first ever guideline on Ebola therapies. In releasing the guideline Aug. 19, WHO officials celebrated the fact that Ebola is no longer “a near certain killer” – provided treatment starts as soon as possible following diagnosis.
Read More
Chess board and pieces, blocks spelling out M&A

Skin in the game: Regeneron buys Checkmate for $250M

April 19, 2022
By Lee Landenberger
Regeneron Pharmaceuticals Inc. proposes to buy Checkmate Pharmaceuticals Inc. though an all-cash price of $10.50 per share for about $250 million. That’s pretty much on target with Checkmate’s April 19 closing share price (NASDAQ:CMPI) of $10.35, as the stock gained a staggering 326% on the day.
Read More